Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Mehr anzeigen
Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540...
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the...
NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in...
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.1428 | 13.8973498826 | 29.81 | 34.04 | 28.44 | 2486537 | 31.72960057 | CS |
| 4 | 3.2578 | 10.6134549601 | 30.695 | 34.04 | 27.24 | 2823683 | 29.70183118 | CS |
| 12 | 7.2528 | 27.1640449438 | 26.7 | 36.84 | 26.15 | 2841711 | 31.38809448 | CS |
| 26 | 13.3028 | 64.4203389831 | 20.65 | 36.84 | 16.8901 | 3271016 | 26.26405689 | CS |
| 52 | 18.1228 | 114.483891346 | 15.83 | 36.84 | 12.84 | 3255154 | 21.35186906 | CS |
| 156 | 24.0628 | 243.304347826 | 9.89 | 36.84 | 3.48 | 3860867 | 15.23285221 | CS |
| 260 | 19.7028 | 138.265263158 | 14.25 | 56.74 | 3.48 | 3014992 | 18.04086472 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| NVDANVIDIA Corporation | US$ 121,8496 (-5,54%) | 316,91M |
| SLXNSilexion Therapeutics Corporation | US$ 3,0801 (128,16%) | 296,73M |
| OCEAOcean Biomedical Inc | US$ 0,2722 (-17,52%) | 177,13M |
| RIMEAlgorhythm Holdings Inc | US$ 0,0275 (-11,00%) | 114,77M |
| TNXPTonix Pharmaceuticals Holding Corporation | US$ 0,445519 (-3,17%) | 108,89M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
